had same question myself, but look at cohort, complex interuptions can delay... maybe they are being more prudent this time... wont matter if fx speeds up the cx with good results... ?
I had the same question but found the answer in the updated presentation on their website. Last enrollment isn't expected until July 2016 even though the first group is July 2015, which then lasts a year, and then a few months to compile the data brings us to q417. Having to wait almost three years wasn't expected (at least by me) which is probably why the stock price is sinking again. I was really hoping we'd have some results reported by the end of the year.
From the presentation they are expecting enrolment to take a year. Expecting last patient last visit Aug 2017. The shorter FX trial should hopefully be long enough to see the true effect of this drug. The Cohort 3 FibroScan showed greatly improving results with increasing time 2 patients were noticed to have 50% drop and 1 with 30% after 60days. The FX trial will be twice as long with 9 doses vs 4. Hopefully all 20 enrolled see a 50%+ drop and GALT can get Breakthrough designation. Get this drug to market as quickly as possible, so as to save as many lives as possible.
News 
Market Data 
Discover 
